Home / Health care / labiotech : reported that A New HIV Therapy uses DNA and Antibodies to fight Viral Reservoirs
alibaba.com, cpa campaign, lead generation, lead campaign, smart match lander, intelligent lander, a

labiotech : reported that A New HIV Therapy uses DNA and Antibodies to fight Viral Reservoirs

This content may collect you by Victoria Hunter

We will quote to you most important and trendy news about all kind of Therapy of the best health sites Like : “labiotech” and the most famous medical experts :

daily : 2017-01-11 & on time : 13:28

according to

A New HIV Therapy uses DNA and Antibodies to fight Viral Reservoirs

A New HIV Therapy uses DNA and Antibodies to fight Viral Reservoirs

image uploaded by “labiotech” site

Mologen’s partner in the development of an HIV therapy has received a €2.6M grant to evaluate a promising new combination therapy in the clinic.Berlin-based Mologen is working with the Aarhus University Hospital in Denmark to develop lefitolimod, an immunomodulatory HIV treatment.The candidate will now be tested in combination with neutralizing antibodies developed by Rockefeller University in New York thanks to a €2.6M ($2.75M) grant from Gilead, which is also working on its own HIV therapy.

about the details read more from here

CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy Other OTC

CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy Other OTC

image uploaded by “globenewswire” site

VANCOUVER, Washington, Jan. 11, 2017 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment-experienced patients with virologic failure.While the standard of care for HIV infection has been a combination of medications from different antiretroviral classes that interfere with different steps of the HIV lifecycle, there is now a significant number of long-term survivors who are facing issues of drug resistance and need new treatment options.The Company believes this request for Breakthrough Therapy Designation addresses this unmet need for novel therapies for the growing number of heavily treatment-experienced HIV patients.

about the details read more from here

CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy

CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy

image uploaded by “nasdaq” site

VANCOUVER, Washington, Jan. 11, 2017 (GLOBE NEWSWIRE) — CytoDyn Inc.(OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment-experienced patients with virologic failure.While the standard of care for HIV infection has been a combination of medications from different antiretroviral classes that interfere with different steps of the HIV lifecycle, there is now a significant number of long-term survivors who are facing issues of drug resistance and need new treatment options.The Company believes this request for Breakthrough Therapy Designation addresses this unmet need for novel therapies for the growing number of heavily treatment-experienced HIV patients.

about the details read more from here

To follow all the new news about Therapy

Check Also

picture.jpg

interchange | Brain tumour patient uses art as medication

In Bedford County, an artist is using her work as a form of medication. She …